Tower Research Capital (TRC)’s Lantern Pharma LTRN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$4.89K Buy
3,569
+2,728
+324% +$7.63K ﹤0.01% 4160
2025
Q4
$2.55K Buy
841
+411
+96% +$1.53K ﹤0.01% 4504
2025
Q3
$1.87K Sell
430
-727
-63% -$3.03K ﹤0.01% 4719
2025
Q2
$3.66K Buy
1,157
+365
+46% +$1.23K ﹤0.01% 4454
2025
Q1
$2.8K Sell
792
-471
-37% -$1.95K ﹤0.01% 4504
2024
Q4
$4.03K Sell
1,263
-252
-17% -$863 ﹤0.01% 4536
2024
Q3
$5.56K Buy
1,515
+176
+13% +$725 ﹤0.01% 4251
2024
Q2
$6.25K Sell
1,339
-2,017
-60% -$12.1K ﹤0.01% 4600
2024
Q1
$29.5K Buy
3,356
+2,192
+188% +$11.7K ﹤0.01% 2665
2023
Q4
$4.98K Sell
1,164
-693
-37% -$2.44K ﹤0.01% 4891
2023
Q3
$6.33K Sell
1,857
-482
-21% -$2.19K ﹤0.01% 4612
2023
Q2
$13.2K Buy
2,339
+222
+10% +$1.15K ﹤0.01% 3797
2023
Q1
$10K Buy
2,117
+2,089
+7,461% +$11K ﹤0.01% 4367
2022
Q4
$0 Sell
28
-3,789
-99% -$19K ﹤0.01% 6177
2022
Q3
$19K Buy
3,817
+2,690
+239% +$14.5K ﹤0.01% 3976
2022
Q2
$6K Buy
1,127
+354
+46% +$2.11K ﹤0.01% 4935
2022
Q1
$6K Sell
773
-839
-52% -$5.6K ﹤0.01% 4898
2021
Q4
$13K Buy
1,612
+1,082
+204% +$9.88K ﹤0.01% 4187
2021
Q3
$6K Buy
530
+178
+51% +$2.3K ﹤0.01% 4762
2021
Q2
$5K Buy
352
+290
+468% +$4.48K ﹤0.01% 4726
2021
Q1
$1K Sell
62
-531
-90% -$9.31K ﹤0.01% 5191
2020
Q4
$11K Sell
593
-116
-16% -$2K ﹤0.01% 4249
2020
Q3
$13K Buy
709
+539
+317% +$7.8K ﹤0.01% 3993
2020
Q2
$2K Buy
+170
New +$2.2K ﹤0.01% 4513

Other funds holding LTRN

Tower Research Capital (TRC)'s LTRN Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Lantern Pharma (LTRN) stake by 324% in Q1 2026, buying an estimated $7.63K and bringing the position to 3,569 shares worth $4.89K. The position accounts for ﹤0.01% of the portfolio, ranked #4160.

Tower Research Capital (TRC) first reported a position in LTRN in Q2 2020 and has held it in 24 quarters since. The position peaked at $29.5K in Q1 2024. 33 funds tracked by Wall St. Rank hold LTRN as of Q1 2026.

  • Tower Research Capital (TRC) held 3,569 shares of Lantern Pharma worth $4.89K as of Q1 2026.
  • Tower Research Capital (TRC) bought 2,728 Lantern Pharma shares in Q1 2026, an estimated $7.63K.
  • Lantern Pharma made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #4160 holding.
  • Tower Research Capital (TRC) first reported a position in Lantern Pharma in Q2 2020 and has held it in 24 quarters since.
  • Tower Research Capital (TRC)'s Lantern Pharma position peaked at $29.5K in Q1 2024.
  • 33 funds tracked by Wall St. Rank held Lantern Pharma as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.